Showing results (1-10 of 1,096) with videos related to
Sort By:
Pageof 110
Journal of Diabetes and Its Complications|March 19, 2015
Increasing body mass index identifies Chinese patients with type 2 diabetes mellitus at risk of poor outcomesLinong Ji, Dajin Zou, Li Liu, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 28, 2021
Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes MellitusXiaoling Cai, Linong JiJournal of Diabetes Research|October 11, 2021
Clinical and Genetic Characteristics of ABCC8 Nonneonatal Diabetes Mellitus: A Systematic ReviewMeng Li, Xueyao Han, Linong JiJournal of Diabetes and Its Complications|August 26, 2023
Association between remnant cholesterol level and severity of chronic kidney disease in patients with type 2 diabetesYanping Yuan, Xianghai Zhou, Linong JiDigital Health|October 3, 2023
Review: Machine learning in precision pharmacotherapy of type 2 diabetes-A promising future or a glimpse of hope?Xiantong Zou, Yingning Liu, Linong JiCalcified Tissue International|June 29, 2022
An Update on Animal Models of Osteogenesis ImperfectaFang Lv, Xiaoling Cai, Linong JiZhonghua Yi Xue Za Zhi|January 3, 2003
[The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population]Fang Zhu, Linong Ji, Bin LuoThe Journal of Clinical Endocrinology and Metabolism|August 30, 2024
Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular DiseaseChaochao Yang, Linong Ji, Xueyao HanBeijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|April 14, 2026
[False positives in female testosterone testing and the diagnostic value of mass spectrometry]Man Wu, Yingying Luo, Linong JiEclinicalmedicine|August 25, 2021
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyLinong Ji, Hongwei Jiang, Pei An, et al.Pageof 110